Jeffery Sonnenfeld of the Yale School of Management chats with The Deal Pipeline about the most important themes that were discussed during the town hall he led on Dec. 1 at The Deal Economy 2012 event. Among those issues were regulation and uncalibrated risk in the U.S. as they relate to Europe's debt issues. - Sarah Hashim-Waris
Three directors are leaving Valeant Pharmaceuticals International's board, including Warburg Pincus' Fred Hassan, ValueAct's G. Mason Morfit and Persistence Capital's Lloyd M. Segal. For other updates launch today's Movers & shakers slideshow.